<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ahmad, Jamal</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Incobotulinum Toxin a Effective in Treating Plantar Fasciitis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Up to 2 million patients per year require treatment for plantar fasciitis, with risk factors including prolonged weight-bearing activity, inappropriate shoe wear, greater body weight, and medical comorbidities. This article discusses data from the Treatment of Plantar Fasciitis With Xeomin study [NCT01678001], which evaluated long-term outcomes of patients with plantar fasciitis treated with incobotulinum toxin A.</style></abstract><number><style face="normal" font="default" size="100%">34</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>